Top Obesity Research Papers

Overall: This large randomized-trial synthesis is clinically influential and directly applicable to US obesity care, but limited head-to-head comparisons, sparse hard-outcome evidence, increased adverse-event discontinuation, and absent absolute effects temper confidence in the net benefit.

Overall: This large observational study links simple central-adiposity measures to clinically important cardiovascular outcomes, but it does not establish that risk reclassification improves treatment or patient outcomes.

Overall: This rigorous but small trial found substantial weight loss with semaglutide in a specialized post-bariatric population, with promising clinical relevance tempered by limited patient-outcome data, safety events, and implementation barriers.

Overall: A very large contemporary US cohort links BMI and diabetes with gestational-age-specific stillbirth risk, but its observational design and lack of complete absolute effects or tested delivery strategies limit immediate practice change.

Overall: This prespecified randomized-trial analysis provides credible evidence that semaglutide retains cardiovascular benefit in a primary-care-relevant high-risk subgroup, but absent absolute effects and safety data and reliance on a surrogate liver measure limit its independent practice-changing impact.

Overall: A large, precise cohort provides clinically relevant dietary guidance for menopausal weight management, but observational evidence, self-reported outcomes, and limited novelty constrain practice-changing impact.

Overall: This well-controlled trial suggests that oral orforglipron can preserve weight loss after injectable therapy, but missing absolute weight effects, limited patient-important outcomes, and no active comparator temper its immediate practice-changing value.

Overall: A large and methodologically strong synthesis identifies several effective pharmacologic options for antipsychotic-associated weight gain, but specialist overlap, implementation barriers, and the absence of direct patient-important clinical outcomes limit its impact for routine US primary care.

Overall: This large US observational study links GLP-1 receptor agonist use with substantial improvements in survival and recurrence outcomes, but residual confounding, absent absolute benefit and safety data, and the need for randomized confirmation limit current practice implications.

Overall: Family-Centered Child Obesity Treatment: The TEAM UP Randomized Clinical Trial provides strong, directly applicable randomized evidence that primary-care-integrated family treatment improves relative weight, although patient-important gains were modest and implementation may be resource intensive.